Since O‐GlcNAc cycling is altered in patients with AD (Forster et al., 2014; Liu et al., 2009; Zhu et al., 2014), we hypothesized that c‐Fos O‐GlcNAcylation might be dysregulated in AD and play a role in its pathogenesis. This evidence concerns the gene FOS and Alzheimer disease.